# A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

> **NCT06016556** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 250 (actual)

## Conditions studied

- Covid-19

## Interventions

- **DRUG:** nirmatrelvir, ritonavir

## Key facts

- **NCT ID:** NCT06016556
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-17
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016556, "A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06016556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*